51
|
Kamiya Y, Yamada Y, Muro T, Matsuura K, Asanuma H. DNA Microcapsule for Photo-Triggered Drug Release Systems. ChemMedChem 2017; 12:2016-2021. [DOI: 10.1002/cmdc.201700512] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2017] [Revised: 09/21/2017] [Indexed: 12/20/2022]
Affiliation(s)
- Yukiko Kamiya
- Department of Biomolecular Engineering; Graduate School of Engineering; Nagoya University; Furo-cho Chikusa-ku Nagoya 464-8603 Japan
- Institute of Materials and Systems for Sustainability; Nagoya University; Furo-cho Chikusa-ku Nagoya 464-8603 Japan
| | - Yoshinobu Yamada
- Department of Biomolecular Engineering; Graduate School of Engineering; Nagoya University; Furo-cho Chikusa-ku Nagoya 464-8603 Japan
| | - Takahiro Muro
- Department of Biomolecular Engineering; Graduate School of Engineering; Nagoya University; Furo-cho Chikusa-ku Nagoya 464-8603 Japan
| | - Kazunori Matsuura
- Department of Chemistry and Biotechnology; Graduate School of Engineering; Tottori University; Koyama-Minami 4-101 Tottori 680-8552 Japan
| | - Hiroyuki Asanuma
- Department of Biomolecular Engineering; Graduate School of Engineering; Nagoya University; Furo-cho Chikusa-ku Nagoya 464-8603 Japan
| |
Collapse
|
52
|
Shafaee MN, Salahudeen AA, Valero V. Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation. J Oncol Pract 2017; 13:555-556. [PMID: 28678590 DOI: 10.1200/jop.2016.020198] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Maryam Nemati Shafaee
- Baylor College of Medicine; The University of Texas Health Science Center at Houston; and The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Ahmed A Salahudeen
- Baylor College of Medicine; The University of Texas Health Science Center at Houston; and The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Vicente Valero
- Baylor College of Medicine; The University of Texas Health Science Center at Houston; and The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
53
|
Li X, Kim J, Yoon J, Chen X. Cancer-Associated, Stimuli-Driven, Turn on Theranostics for Multimodality Imaging and Therapy. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2017; 29:10.1002/adma.201606857. [PMID: 28370546 PMCID: PMC5544499 DOI: 10.1002/adma.201606857] [Citation(s) in RCA: 238] [Impact Index Per Article: 34.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Revised: 02/11/2017] [Indexed: 04/14/2023]
Abstract
Advances in bioinformatics, genomics, proteomics, and metabolomics have facilitated the development of novel anticancer agents that have decreased side effects and increased safety. Theranostics, systems that have combined therapeutic effects and diagnostic capabilities, have garnered increasing attention recently because of their potential use in personalized medicine, including cancer-targeting treatments for patients. One interesting approach to achieving this potential involves the development of cancer-associated, stimuli-driven, turn on theranostics. Multicomponent constructs of this type would have the capability of selectively delivering therapeutic reagents into cancer cells or tumor tissues while simultaneously generating unique signals that can be readily monitored under both in vitro and in vivo conditions. Specifically, their combined anticancer activities and selective visual signal respond to cancer-associated stimuli, would make these theranostic agents more highly efficient and specific for cancer treatment and diagnosis. This article focuses on the progress of stimuli-responsive turn on theranostics that activate diagnostic signals and release therapeutic reagents in response to the cancer-associated stimuli. The present article not only provides the fundamental backgrounds of diagnostic and therapeutic tools that have been widely utilized for developing theranostic agents, but also discusses the current approaches for developing stimuli-responsive turn on theranostics.
Collapse
Affiliation(s)
- Xingshu Li
- Department of Chemistry and Nano Science, Ewha Womans University, Seoul, 120-750, Korea
| | - Jihoon Kim
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, Maryland, 20892, USA
| | - Juyoung Yoon
- Department of Chemistry and Nano Science, Ewha Womans University, Seoul, 120-750, Korea
| | - Xiaoyuan Chen
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, Maryland, 20892, USA
| |
Collapse
|
54
|
Botzanowski T, Erb S, Hernandez-Alba O, Ehkirch A, Colas O, Wagner-Rousset E, Rabuka D, Beck A, Drake PM, Cianférani S. Insights from native mass spectrometry approaches for top- and middle- level characterization of site-specific antibody-drug conjugates. MAbs 2017; 9:801-811. [PMID: 28406343 DOI: 10.1080/19420862.2017.1316914] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Antibody-drug conjugates (ADCs) have emerged as a family of compounds with promise as efficient immunotherapies. First-generation ADCs were generated mostly via reactions on either lysine side-chain amines or cysteine thiol groups after reduction of the interchain disulfide bonds, resulting in heterogeneous populations with a variable number of drug loads per antibody. To control the position and the number of drug loads, new conjugation strategies aiming at the generation of more homogeneous site-specific conjugates have been developed. We report here the first multi-level characterization of a site-specific ADC by state-of-the-art mass spectrometry (MS) methods, including native MS and its hyphenation to ion mobility (IM-MS). We demonstrate the versatility of native MS methodologies for site-specific ADC analysis, with the unique ability to provide several critical quality attributes within one single run, along with a direct snapshot of ADC homogeneity/heterogeneity without extensive data interpretation. The capabilities of native IM-MS to directly access site-specific ADC conformational information are also highlighted. Finally, the potential of these techniques for assessing an ADC's heterogeneity/homogeneity is illustrated by comparing the analytical characterization of a site-specific DAR4 ADC to that of first-generation ADCs. Altogether, our results highlight the compatibility, versatility, and benefits of native MS approaches for the analytical characterization of all types of ADCs, including site-specific conjugates. Thus, we envision integrating native MS and IM-MS approaches, even in their latest state-of-the-art forms, into workflows that benchmark bioconjugation strategies.
Collapse
Affiliation(s)
- Thomas Botzanowski
- a Laboratoire de Spectrométrie de Masse BioOrganique, Université de Strasbourg, CNRS , Strasbourg , France
| | - Stéphane Erb
- a Laboratoire de Spectrométrie de Masse BioOrganique, Université de Strasbourg, CNRS , Strasbourg , France
| | - Oscar Hernandez-Alba
- a Laboratoire de Spectrométrie de Masse BioOrganique, Université de Strasbourg, CNRS , Strasbourg , France
| | - Anthony Ehkirch
- a Laboratoire de Spectrométrie de Masse BioOrganique, Université de Strasbourg, CNRS , Strasbourg , France
| | - Olivier Colas
- b Centre d'Immunologie Pierre-Fabre (CIPF) , Saint-Julien-en-Genevois , France
| | - Elsa Wagner-Rousset
- b Centre d'Immunologie Pierre-Fabre (CIPF) , Saint-Julien-en-Genevois , France
| | - David Rabuka
- c Catalent Biologics West , Emeryville , CA , USA
| | - Alain Beck
- b Centre d'Immunologie Pierre-Fabre (CIPF) , Saint-Julien-en-Genevois , France
| | | | - Sarah Cianférani
- a Laboratoire de Spectrométrie de Masse BioOrganique, Université de Strasbourg, CNRS , Strasbourg , France
| |
Collapse
|
55
|
Li X, Nelson CG, Nair RR, Hazlehurst L, Moroni T, Martinez-Acedo P, Nanna AR, Hymel D, Burke TR, Rader C. Stable and Potent Selenomab-Drug Conjugates. Cell Chem Biol 2017; 24:433-442.e6. [PMID: 28330604 DOI: 10.1016/j.chembiol.2017.02.012] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2016] [Revised: 12/16/2016] [Accepted: 02/10/2017] [Indexed: 02/06/2023]
Abstract
Selenomabs are engineered monoclonal antibodies with one or more translationally incorporated selenocysteine residues. The unique reactivity of the selenol group of selenocysteine permits site-specific conjugation of drugs. Compared with other natural and unnatural amino acid and carbohydrate residues that have been used for the generation of site-specific antibody-drug conjugates, selenocysteine is particularly reactive, permitting fast, single-step, and efficient reactions under near physiological conditions. Using a tailored conjugation chemistry, we generated highly stable selenomab-drug conjugates and demonstrated their potency and selectivity in vitro and in vivo. These site-specific antibody-drug conjugates built on a selenocysteine interface revealed broad therapeutic utility in liquid and solid malignancy models.
Collapse
Affiliation(s)
- Xiuling Li
- Department of Cancer Biology, The Scripps Research Institute, Jupiter, FL 33458, USA
| | - Christopher G Nelson
- Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA
| | - Rajesh R Nair
- Molecular Oncology Program, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA
| | - Lori Hazlehurst
- Molecular Oncology Program, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA
| | - Tina Moroni
- Proteomics and Mass Spectrometry Core, The Scripps Research Institute, Jupiter, FL 33458, USA
| | - Pablo Martinez-Acedo
- Proteomics and Mass Spectrometry Core, The Scripps Research Institute, Jupiter, FL 33458, USA
| | - Alex R Nanna
- Department of Cancer Biology, The Scripps Research Institute, Jupiter, FL 33458, USA
| | - David Hymel
- Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA
| | - Terrence R Burke
- Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA
| | - Christoph Rader
- Department of Cancer Biology, The Scripps Research Institute, Jupiter, FL 33458, USA; Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL 33458, USA.
| |
Collapse
|
56
|
Jhan SY, Huang LJ, Wang TF, Chou HH, Chen SH. Dimethyl Labeling Coupled with Mass Spectrometry for Topographical Characterization of Primary Amines on Monoclonal Antibodies. Anal Chem 2017; 89:4255-4263. [PMID: 28257187 DOI: 10.1021/acs.analchem.7b00320] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Site-specific solvent accessibility of the primary amines (mainly lysine or the N-termini) on proteins is of great interest in many research areas because amines are an important functional group for protein conjugation. In this study, we coupled dimethyl labeling via reductive amination with liquid chromatography-mass spectrometry (LC-MS) to fully characterize the solvent accessibility of lysine residues and the N-termini on human immunoglobulin G (IgG). Circular dichroism (CD) and fluorescence spectroscopy revealed that dimethyl labeling did not alter the conformation of the native IgG molecule. Based on intact protein measurements, up to 28 (light chain) and 66 (heavy chain) dimethyl tags, covering all lysine residues and the N-termini, were sequentially incorporated into IgG molecules in 1000 s. All labeled sites were identified and quantified by a bottom-up proteomics approach. Some highly exposed hot-spots (for example, the N-termini of both the heavy and the light chains) and some buried sites (for example, K415 in the heavy chain and K39 in the light chain) were unambiguously revealed. This method was also used to characterize aggregation-induced structural changes in IgGs by increasing the temperature. Substantial changes in the labeling percentage of many lysine sites were observed, indicating a non-native aggregation triggered by thermal stress. Due to high labeling yields and the van der Waals surface of the labeling reagents being comparable to that of water, dimethyl labeling is a highly promising technique for probing the amine's surface topography of proteins. It can also be used as a complementary approach to other methods for resolving the higher-order structure of proteins by LC-MS.
Collapse
Affiliation(s)
- Sin-Yi Jhan
- Department of Chemistry, National Cheng Kung University , No. 1 College Road, Tainan 701, Taiwan, Republic of China
| | - Li-Juan Huang
- Department of Chemistry, National Cheng Kung University , No. 1 College Road, Tainan 701, Taiwan, Republic of China
| | - Tzu-Fan Wang
- Department of Chemistry, National Cheng Kung University , No. 1 College Road, Tainan 701, Taiwan, Republic of China
| | - Ho-Hsuan Chou
- Department of Chemistry, National Cheng Kung University , No. 1 College Road, Tainan 701, Taiwan, Republic of China
| | - Shu-Hui Chen
- Department of Chemistry, National Cheng Kung University , No. 1 College Road, Tainan 701, Taiwan, Republic of China
| |
Collapse
|
57
|
Gupta N, Kancharla J, Kaushik S, Ansari A, Hossain S, Goyal R, Pandey M, Sivaccumar J, Hussain S, Sarkar A, Sengupta A, Mandal SK, Roy M, Sengupta S. Development of a facile antibody-drug conjugate platform for increased stability and homogeneity. Chem Sci 2017; 8:2387-2395. [PMID: 28451344 PMCID: PMC5369337 DOI: 10.1039/c6sc05149a] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2016] [Accepted: 12/07/2016] [Indexed: 11/21/2022] Open
Abstract
Despite the advances in the design of antibody-drug conjugates (ADCs), the search is still ongoing for novel approaches that lead to increased stability and homogeneity of the ADCs. We report, for the first time, an ADC platform technology using a platinum(ii)-based linker that can re-bridge the inter-chain cysteines in the antibody, post-reduction. The strong platinum-sulfur interaction improves the stability of the ADC when compared with a standard maleimide-linked ADC thereby reducing the linker-drug exchange with albumin significantly. Moreover, due to the precise conserved locations of cysteines, both homogeneity and site-specificity are simultaneously achieved. Additionally, we demonstrate that our ADCs exhibit increased anticancer efficacy in vitro and in vivo. The Pt-based ADCs can emerge as a simple and exciting proposition to address the limitations of the current ADC linker technologies.
Collapse
Affiliation(s)
- Nimish Gupta
- Invictus Oncology Pvt. Ltd. , Delhi-110092 , India . ;
- India Innovation Research Center , Delhi-110092 , India
- Health and Biomedical Sciences , Symbiosis International University , Pune-412115 , India
| | | | | | - Aasif Ansari
- Invictus Oncology Pvt. Ltd. , Delhi-110092 , India . ;
| | - Samad Hossain
- Invictus Oncology Pvt. Ltd. , Delhi-110092 , India . ;
- India Innovation Research Center , Delhi-110092 , India
- Health and Biomedical Sciences , Symbiosis International University , Pune-412115 , India
| | | | - Manoj Pandey
- Invictus Oncology Pvt. Ltd. , Delhi-110092 , India . ;
| | | | - Sazid Hussain
- Invictus Oncology Pvt. Ltd. , Delhi-110092 , India . ;
| | - Arindam Sarkar
- Invictus Oncology Pvt. Ltd. , Delhi-110092 , India . ;
- India Innovation Research Center , Delhi-110092 , India
- Health and Biomedical Sciences , Symbiosis International University , Pune-412115 , India
| | - Aniruddha Sengupta
- Invictus Oncology Pvt. Ltd. , Delhi-110092 , India . ;
- India Innovation Research Center , Delhi-110092 , India
- Health and Biomedical Sciences , Symbiosis International University , Pune-412115 , India
| | - Swadhin K Mandal
- Department of Chemical Sciences , Indian Institute of Science Education and Research-Kolkata , Mohanpur-741252 , India
| | - Monideepa Roy
- Invictus Oncology Pvt. Ltd. , Delhi-110092 , India . ;
- India Innovation Research Center , Delhi-110092 , India
- Health and Biomedical Sciences , Symbiosis International University , Pune-412115 , India
| | - Shiladitya Sengupta
- Invictus Oncology Pvt. Ltd. , Delhi-110092 , India . ;
- India Innovation Research Center , Delhi-110092 , India
- Brigham and Women's Hospital , Harvard Medical School , Boston , MA 02115 , USA
- Harvard - MIT Division of Health Sciences and Technology , Cambridge , MA 02139 , USA
| |
Collapse
|
58
|
Chilamari M, Purushottam L, Rai V. Site-Selective Labeling of Native Proteins by a Multicomponent Approach. Chemistry 2017; 23:3819-3823. [DOI: 10.1002/chem.201605938] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Indexed: 01/08/2023]
Affiliation(s)
- Maheshwerreddy Chilamari
- Organic and Bioconjugate Chemistry Laboratory (OBCL), Department of Chemistry; Indian Institute of Science Education and Research Bhopal; Bhauri Bhopal 462 066 India
| | - Landa Purushottam
- Organic and Bioconjugate Chemistry Laboratory (OBCL), Department of Chemistry; Indian Institute of Science Education and Research Bhopal; Bhauri Bhopal 462 066 India
| | - Vishal Rai
- Organic and Bioconjugate Chemistry Laboratory (OBCL), Department of Chemistry; Indian Institute of Science Education and Research Bhopal; Bhauri Bhopal 462 066 India
| |
Collapse
|
59
|
Ariyasu S, Hayashi H, Xing B, Chiba S. Site-Specific Dual Functionalization of Cysteine Residue in Peptides and Proteins with 2-Azidoacrylates. Bioconjug Chem 2017; 28:897-902. [DOI: 10.1021/acs.bioconjchem.7b00024] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Shinya Ariyasu
- Division
of Chemistry and Biological Chemistry, School of Physical and Mathematical
Sciences, Nanyang Technological University, 637371 Singapore
| | - Hirohito Hayashi
- Division
of Chemistry and Biological Chemistry, School of Physical and Mathematical
Sciences, Nanyang Technological University, 637371 Singapore
| | - Bengang Xing
- Division
of Chemistry and Biological Chemistry, School of Physical and Mathematical
Sciences, Nanyang Technological University, 637371 Singapore
| | - Shunsuke Chiba
- Division
of Chemistry and Biological Chemistry, School of Physical and Mathematical
Sciences, Nanyang Technological University, 637371 Singapore
| |
Collapse
|
60
|
Valeur E, Knerr L, Ölwegård-Halvarsson M, Lemurell M. Targeted delivery for regenerative medicines: an untapped opportunity for drug conjugates. Drug Discov Today 2016; 22:841-847. [PMID: 27988360 DOI: 10.1016/j.drudis.2016.12.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2016] [Revised: 12/05/2016] [Accepted: 12/08/2016] [Indexed: 11/18/2022]
Abstract
Regenerative approaches are promising avenues to effectively cure diseases rather than merely treating symptoms, but are associated with concerns around proliferation in other organs. Given that targeted delivery holds the promise of delivering a drug precisely to its desired site of action, usually with the prospect of increasing the therapeutic index, it can be considered as an essential enabler of regenerative medicines. Although significant progress has been made predominantly in oncology for the delivery of cytotoxic drugs using antibody-drug conjugates (ADCs), the physiological conditions and safety requirements for regenerative medicines are very different. Drug conjugates need to be approached differently and, we herein suggest using a broader range of homing modalities and a specific framework to develop safe linkers.
Collapse
Affiliation(s)
- Eric Valeur
- Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Pepparedsleden 1, Mölndal 431 83, Sweden.
| | - Laurent Knerr
- Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Pepparedsleden 1, Mölndal 431 83, Sweden
| | - Maria Ölwegård-Halvarsson
- Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Pepparedsleden 1, Mölndal 431 83, Sweden
| | - Malin Lemurell
- Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Pepparedsleden 1, Mölndal 431 83, Sweden
| |
Collapse
|
61
|
Ekholm FS, Pynnönen H, Vilkman A, Pitkänen V, Helin J, Saarinen J, Satomaa T. Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry. ChemMedChem 2016; 11:2501-2505. [PMID: 27786414 DOI: 10.1002/cmdc.201600372] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2016] [Revised: 09/29/2016] [Indexed: 12/22/2022]
Abstract
Antibody-drug conjugates (ADCs) are promising alternatives to naked antibodies for selective drug-delivery applications and treatment of diseases such as cancer. Construction of ADCs relies upon site-selective, efficient and mild conjugation technologies. The choice of a chemical linker is especially important, as it affects the overall properties of the ADC. We envisioned that hydrophilic bifunctional chemical linkers based on carbohydrates would be a useful class of derivatization agents for the construction of linker-drug conjugates and ADCs. Herein we describe the synthesis of carbohydrate-based derivatization agents, glycolinker-drug conjugates featuring the tubulin inhibitor monomethyl auristatin E and an ADC based on an anti-EGFR antibody. In addition, an initial in vitro cytotoxicity evaluation of the individual components and the ADC is provided against EGFR-positive cancer cells.
Collapse
Affiliation(s)
- Filip S Ekholm
- Glykos Finland Ltd., Viikinkaari 6, 00790, Helsinki, Finland.,Department of Chemistry, University of Helsinki, PO Box 55, A. I. Virtasen aukio 1, 00014, Helsinki, Finland
| | - Henna Pynnönen
- Glykos Finland Ltd., Viikinkaari 6, 00790, Helsinki, Finland
| | - Anja Vilkman
- Glykos Finland Ltd., Viikinkaari 6, 00790, Helsinki, Finland
| | - Virve Pitkänen
- Glykos Finland Ltd., Viikinkaari 6, 00790, Helsinki, Finland
| | - Jari Helin
- Glykos Finland Ltd., Viikinkaari 6, 00790, Helsinki, Finland
| | - Juhani Saarinen
- Glykos Finland Ltd., Viikinkaari 6, 00790, Helsinki, Finland
| | - Tero Satomaa
- Glykos Finland Ltd., Viikinkaari 6, 00790, Helsinki, Finland
| |
Collapse
|
62
|
Fu Y, Feng Q, Chen Y, Shen Y, Su Q, Zhang Y, Zhou X, Cheng Y. Comparison of Two Approaches for the Attachment of a Drug to Gold Nanoparticles and Their Anticancer Activities. Mol Pharm 2016; 13:3308-17. [PMID: 27518201 DOI: 10.1021/acs.molpharmaceut.6b00619] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Yingjie Fu
- College
of Chemistry and Molecular Science, The Institute for Advanced Studies, Wuhan University, Wuhan 430072, China
| | - Qishuai Feng
- Shanghai
East Hospital, The Institute for Biomedical Engineering and Nano Science, Tongji University School of Medicine, Shanghai 200029, China
| | - Yifan Chen
- Shanghai
East Hospital, The Institute for Biomedical Engineering and Nano Science, Tongji University School of Medicine, Shanghai 200029, China
| | - Yajing Shen
- Shanghai
East Hospital, The Institute for Biomedical Engineering and Nano Science, Tongji University School of Medicine, Shanghai 200029, China
| | - Qihang Su
- Shanghai
East Hospital, The Institute for Biomedical Engineering and Nano Science, Tongji University School of Medicine, Shanghai 200029, China
| | - Yinglei Zhang
- Shanghai
East Hospital, The Institute for Biomedical Engineering and Nano Science, Tongji University School of Medicine, Shanghai 200029, China
| | - Xiang Zhou
- College
of Chemistry and Molecular Science, The Institute for Advanced Studies, Wuhan University, Wuhan 430072, China
| | - Yu Cheng
- Shanghai
East Hospital, The Institute for Biomedical Engineering and Nano Science, Tongji University School of Medicine, Shanghai 200029, China
| |
Collapse
|
63
|
Chen L, Cohen J, Song X, Zhao A, Ye Z, Feulner CJ, Doonan P, Somers W, Lin L, Chen PR. Improved variants of SrtA for site-specific conjugation on antibodies and proteins with high efficiency. Sci Rep 2016; 6:31899. [PMID: 27534437 PMCID: PMC4989145 DOI: 10.1038/srep31899] [Citation(s) in RCA: 73] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2016] [Accepted: 07/26/2016] [Indexed: 11/19/2022] Open
Abstract
Sortase mediated ligation is a highly specific platform for conjugation that relies on the specificity of the transpeptidase Sortase A (SrtA) for short peptide sequences (LPXTG and GGG). SrtA retains its specificity while accepting a wide range of potential substrates, but its broad use is limited by the wild-type enzyme’s poor kinetics, which require large amounts of SrtA and extended reaction times for efficient conjugation. Prior explorations have aimed to improve the kinetics of SrtA with limited success. Herein we describe the discovery of further improved SrtA variants with increased efficiency for the conjugation reaction, and demonstrate their robustness in labelling proteins and antibodies in a site-specific manner. Our variants require significantly lower amounts of enzyme than WT SrtA and can be used to attach small molecules to the N or C-terminus of the heavy or light chain in antibodies with excellent yields. These improved variants can also be used for highly efficient site-specific PEGylation.
Collapse
Affiliation(s)
- Long Chen
- Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Synthetic and Functional Biomolecules Center, Peking University, Beijing 100871, China
| | - Justin Cohen
- Department of Global Biotherapeutics Technologies, Pfizer Inc., Cambridge, MA 02140, USA
| | - Xiaoda Song
- School of Life Sciences, Nanjing University, China
| | - Aishan Zhao
- Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Synthetic and Functional Biomolecules Center, Peking University, Beijing 100871, China
| | - Zi Ye
- Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Synthetic and Functional Biomolecules Center, Peking University, Beijing 100871, China
| | - Christine J Feulner
- Department of Global Biotherapeutics Technologies, Pfizer Inc., Cambridge, MA 02140, USA
| | - Patrick Doonan
- Department of Global Biotherapeutics Technologies, Pfizer Inc., Cambridge, MA 02140, USA
| | - Will Somers
- Department of Global Biotherapeutics Technologies, Pfizer Inc., Cambridge, MA 02140, USA
| | - Laura Lin
- Department of Global Biotherapeutics Technologies, Pfizer Inc., Cambridge, MA 02140, USA
| | - Peng R Chen
- Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Synthetic and Functional Biomolecules Center, Peking University, Beijing 100871, China.,Peking-Tsinghua Center for Life Sciences, Beijing, China
| |
Collapse
|
64
|
Dilek O, Lei Z, Mukherjee K, Bane S. Rapid formation of a stable boron-nitrogen heterocycle in dilute, neutral aqueous solution for bioorthogonal coupling reactions. Chem Commun (Camb) 2016; 51:16992-5. [PMID: 26446871 DOI: 10.1039/c5cc07453c] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Combining 2-formylphenylboronic acid with 4-hydrazinylbenzoic acid in neutral aqueous solution at low, equimolar concentrations of the reagents results in a single, stable product, a 1,2-dihydro-1-hydroxy-2,3,1-benzodiazaborine, in a matter of minutes with no side products. Application of this reaction to protein conjugation demonstrates that the reaction is orthogonal to protein functional groups, and the resulting conjugate withstands SDS-PAGE analysis. This reaction should be particularly useful for couplings that must be performed with low concentrations of reagents under physiologically compatible conditions.
Collapse
Affiliation(s)
- Ozlem Dilek
- Department of Medical Biochemistry, School of Medicine, Istanbul Kemerburgaz University, Bagcilar, Istanbul 34217, Turkey.
| | - Zhen Lei
- Department of Chemistry, Binghamton University, State University of New York, Binghamton, NY 13902, USA.
| | - Kamalika Mukherjee
- Department of Chemistry, Binghamton University, State University of New York, Binghamton, NY 13902, USA.
| | - Susan Bane
- Department of Chemistry, Binghamton University, State University of New York, Binghamton, NY 13902, USA.
| |
Collapse
|
65
|
Ponte JF, Sun X, Yoder NC, Fishkin N, Laleau R, Coccia J, Lanieri L, Bogalhas M, Wang L, Wilhelm S, Widdison W, Pinkas J, Keating TA, Chari R, Erickson HK, Lambert JM. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates. Bioconjug Chem 2016; 27:1588-98. [PMID: 27174129 DOI: 10.1021/acs.bioconjchem.6b00117] [Citation(s) in RCA: 57] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Antibody-drug conjugates (ADCs) have become a widely investigated modality for cancer therapy, in part due to the clinical findings with ado-trastuzumab emtansine (Kadcyla). Ado-trastuzumab emtansine utilizes the Ab-SMCC-DM1 format, in which the thiol-functionalized maytansinoid cytotoxic agent, DM1, is linked to the antibody (Ab) via the maleimide moiety of the heterobifunctional SMCC linker. The pharmacokinetic (PK) data for ado-trastuzumab emtansine point to a faster clearance for the ADC than for total antibody. Cytotoxic agent release in plasma has been reported with nonmaytansinoid, cysteine-linked ADCs via thiol-maleimide exchange, for example, brentuximab vedotin. For Ab-SMCC-DM1 ADCs, however, the main catabolite reported is lysine-SMCC-DM1, the expected product of intracellular antibody proteolysis. To understand these observations better, we conducted a series of studies to examine the stability of the thiol-maleimide linkage, utilizing the EGFR-targeting conjugate, J2898A-SMCC-DM1, and comparing it with a control ADC made with a noncleavable linker that lacked a thiol-maleimide adduct (J2898A-(CH2)3-DM). We employed radiolabeled ADCs to directly measure both the antibody and the ADC components in plasma. The PK properties of the conjugated antibody moiety of the two conjugates, J2898A-SMCC-DM1 and J2898A-(CH2)3-DM (each with an average of 3.0 to 3.4 maytansinoid molecules per antibody), appear to be similar to that of the unconjugated antibody. Clearance values of the intact conjugates were slightly faster than those of the Ab components. Furthermore, J2898A-SMCC-DM1 clears slightly faster than J2898A-(CH2)3-DM, suggesting that there is a fraction of maytansinoid loss from the SMCC-DM1 ADC, possibly through a thiol-maleimide dependent mechanism. Experiments on ex vivo stability confirm that some loss of maytansinoid from Ab-SMCC-DM1 conjugates can occur via thiol elimination, but at a slower rate than the corresponding rate of loss reported for thiol-maleimide links formed at thiols derived by reduction of endogenous cysteine residues in antibodies, consistent with expected differences in thiol-maleimide stability related to thiol pKa. These findings inform the design strategy for future ADCs.
Collapse
Affiliation(s)
- Jose F Ponte
- ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451-1477, United States
| | - Xiuxia Sun
- ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451-1477, United States
| | - Nicholas C Yoder
- ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451-1477, United States
| | - Nathan Fishkin
- ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451-1477, United States
| | - Rassol Laleau
- ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451-1477, United States
| | - Jennifer Coccia
- ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451-1477, United States
| | - Leanne Lanieri
- ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451-1477, United States
| | - Megan Bogalhas
- ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451-1477, United States
| | - Lintao Wang
- ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451-1477, United States
| | - Sharon Wilhelm
- ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451-1477, United States
| | - Wayne Widdison
- ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451-1477, United States
| | - Jan Pinkas
- ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451-1477, United States
| | - Thomas A Keating
- ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451-1477, United States
| | - Ravi Chari
- ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451-1477, United States
| | - Hans K Erickson
- ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451-1477, United States
| | - John M Lambert
- ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451-1477, United States
| |
Collapse
|
66
|
Bessire AJ, Ballard TE, Charati M, Cohen J, Green M, Lam MH, Loganzo F, Nolting B, Pierce B, Puthenveetil S, Roberts L, Schildknegt K, Subramanyam C. Determination of Antibody–Drug Conjugate Released Payload Species Using Directed in Vitro Assays and Mass Spectrometric Interrogation. Bioconjug Chem 2016; 27:1645-54. [DOI: 10.1021/acs.bioconjchem.6b00192] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Andrew J. Bessire
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - T. Eric Ballard
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Manoj Charati
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Justin Cohen
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Michael Green
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - My-Hanh Lam
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Frank Loganzo
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Birte Nolting
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Betsy Pierce
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Sujiet Puthenveetil
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Lee Roberts
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Klaas Schildknegt
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Chakrapani Subramanyam
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
67
|
Chang CH, Wang Y, Zalath M, Liu D, Cardillo TM, Goldenberg DM. Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers. Mol Cancer Ther 2016; 15:1910-9. [PMID: 27207776 DOI: 10.1158/1535-7163.mct-16-0219] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2016] [Accepted: 05/11/2016] [Indexed: 11/16/2022]
Abstract
Sacituzumab govitecan (IMMU-132), an SN-38-conjugated antibody-drug conjugate, is showing promising therapeutic results in a phase I/II trial of patients with advanced Trop-2-expressing, metastatic, solid cancers. As members of the ATP-binding cassette (ABC) transporters confer chemotherapy resistance by active drug efflux, which is a frequent cause of treatment failure, we explored the use of known inhibitors of ABC transporters for improving the therapeutic efficacy of IMMU-132 by overcoming SN-38 resistance. Two human tumor cell lines made resistant to SN-38, MDA-MB-231-S120 (human breast cancer) and NCI-N87-S120 (human gastric cancer), were established by continuous exposure of the parental cells to stepwise increased concentrations of SN-38 and analyzed by flow cytometry for functional activities of ABCG2 and ABCB1, immunoblotting and qRT-PCR for the expression of ABCG2 at both protein and mRNA levels, and MTS assays for the potency of SN-38 alone or in combination with a modulator of ABC transporters. MDA-MB-231-S120 and NCI-N87-S120 displayed reduced sensitivity to SN-38 in vitro, with IC50 values approximately 50-fold higher than parental MDA-MB-231 and NCI-N87 cells. The increase in drug resistance of both S120 cell populations is associated with the expression of functional ABCG2, but not ABCB1. Importantly, treatment of both S120 sublines with known ABCG2 inhibitors (fumitremorgin C, Ko143, and YHO-13351) restored toxicity of SN-38, and the combination of YHO-13351 with IMMU-132 increased the median survival of mice bearing NCI-N87-S120 xenografts. These results provide a rationale for combination therapy of IMMU-132 and inhibitors of ABC transporters, such as YHO-13351. Mol Cancer Ther; 15(8); 1910-9. ©2016 AACR.
Collapse
MESH Headings
- ATP Binding Cassette Transporter, Subfamily G, Member 2/antagonists & inhibitors
- ATP Binding Cassette Transporter, Subfamily G, Member 2/genetics
- ATP Binding Cassette Transporter, Subfamily G, Member 2/metabolism
- Animals
- Antibodies, Monoclonal/pharmacology
- Antibodies, Monoclonal, Humanized/pharmacology
- Antigens, Neoplasm/genetics
- Antigens, Neoplasm/metabolism
- Breast Neoplasms/drug therapy
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- Camptothecin/analogs & derivatives
- Camptothecin/pharmacology
- Cell Adhesion Molecules/antagonists & inhibitors
- Cell Adhesion Molecules/genetics
- Cell Adhesion Molecules/metabolism
- Cell Line, Tumor
- Cell Survival
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm
- Female
- Flow Cytometry
- Gene Expression
- Humans
- Immunoconjugates/pharmacology
- Inhibitory Concentration 50
- Irinotecan
- Mice
- Stomach Neoplasms/drug therapy
- Stomach Neoplasms/metabolism
- Stomach Neoplasms/pathology
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
| | - Yang Wang
- Immunomedics, Inc. Morris Plains, New Jersey
| | | | - Donglin Liu
- Immunomedics, Inc. Morris Plains, New Jersey
| | | | | |
Collapse
|
68
|
Gunnoo SB, Madder A. Bioconjugation – using selective chemistry to enhance the properties of proteins and peptides as therapeutics and carriers. Org Biomol Chem 2016; 14:8002-13. [DOI: 10.1039/c6ob00808a] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Both peptide and protein therapeutics are becoming increasingly important for treating a wide range of diseases. Functionalisation of theseviasite-selective chemical modification leads to enhancement of their therapeutic properties.
Collapse
Affiliation(s)
- Smita B. Gunnoo
- Organic and Biomimetic Chemistry Research Group
- Department of Organic and Macromolecular Chemistry
- Ghent University
- Ghent
- Belgium
| | - Annemieke Madder
- Organic and Biomimetic Chemistry Research Group
- Department of Organic and Macromolecular Chemistry
- Ghent University
- Ghent
- Belgium
| |
Collapse
|